10. The method of claim 8 or 9, wherein the expression vector includes promoters and other regulators or the like, operably linked to the coding sequence of the expression vector.

11. The method of any one of claims 8 to 10, further including the step of co-infiltration or co-transformation of the plant cell with a suppressor protein adapted to inhibit post-transcriptional gene silencing in a plant.

12. The method of claim 11, wherein the suppressor protein is the NSs protein of the tomato spotted wilt virus or the p19 of tomato bushy stunt virus.

13. The method of any one of claims 8 to 12, wherein the inserted HPV L2 peptide is selected from the group consisting of:

(i) a 13 amino acid peptide of SEQ ID NO: 3 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 7;

(ii) a 20 amino acid peptide of SEQ ID NO: 5 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 9; and

(iii) a 26 amino acid peptide of SEQ ID NO: 4 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 8.

~~14. A method of preventing or treating HPV infection or cervical cancer in a subject, the method comprising administering a therapeutically effective amount of the chimeric HPV VLP of any one of claims 1 to 7 to the subject.~~

~~15. The method of claim 14, further comprising a step of eliciting an immune response in the subject.~~

~~16. The method of claim 15, wherein the immune response is a neutralising antibody response or a cytotoxic T lymphocyte response.~~

~~17. The method of claim 15, wherein the immune response is a cross-protective immune response to multiple HPV types present in the subject.~~

~~18. The method of any one of claims 14 to 17, wherein the subject is human.~~

~~19.~~ 14. A chimaeric HPV VLP of any one of claims 1 to 7 for use in a method of preventing or treating HPV infection or cervical cancer in a subject, the method comprising administering a therapeutically effective amount of the chimaeric HPV VLP to the subject.

~~20.~~ 15. The chimaeric HPV VLP of claim ~~19~~ 14, the method further comprising a step of eliciting an immune response in the subject.

~~21.~~16. The chimaeric HPV VLP of claim ~~20~~15, wherein the immune response is a neutralising antibody response or a cytotoxic T lymphocyte response.

~~22.~~17. The chimaeric HPV VLP of claim ~~20~~15, wherein the immune response is a cross-protective immune response to multiple HPV types present in the subject.

~~23.~~18. The chimaeric HPV VLP of any one of claims ~~19~~ 14 to ~~22~~ 17, wherein the subject is human.

~~24.~~19. The use of chimaeric HPV VLP of any one of claims 1 to 7 in the manufacture of a medicament for use in a method of preventing or treating HPV infection or cervical cancer in a subject, the method comprising administering a therapeutically effective amount of the medicament to the subject.

~~25.~~20. The use of claim ~~24~~19, the method further comprising a step of eliciting an immune response in the subject.

~~26.~~21. The use of claim ~~25~~ 20, wherein the immune response is a neutralising antibody response or a cytotoxic T lymphocyte response.

~~27.~~22. The use of claim ~~25~~ 20, wherein the immune response is a cross-protective immune response to multiple HPV types present in the subject.

~~28.~~23. The use of any one of claims ~~24~~ 19 to ~~27~~ 22, wherein the subject is human.

~~29.~~24. A pharmaceutical composition comprising the chimaeric HPV VLP of any one of claims 1 to 7 and a pharmaceutically acceptable carrier or adjuvant.

10. The method of claim 8 or 9, wherein the expression vector includes promoters and other regulators or the like, operably linked to the coding sequence of the expression vector.

11. The method of any one of claims 8 to 10, further including the step of co-infiltration or co-transformation of the plant cell with a suppressor protein adapted to inhibit post-transcriptional gene silencing in a plant.

12. The method of claim 11, wherein the suppressor protein is the NSs protein of the tomato spotted wilt virus or the p19 of tomato bushy stunt virus.

13. The method of any one of claims 8 to 12, wherein the inserted HPV L2 peptide is selected from the group consisting of:

(i) a 13 amino acid peptide of SEQ ID NO: 3 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 7;

(ii) a 20 amino acid peptide of SEQ ID NO: 5 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 9; and

(iii) a 26 amino acid peptide of SEQ ID NO: 4 encoded by a human codon-optimised nucleotide sequence of SEQ ID NO: 8.

14. A chimaeric HPV VLP of any one of claims 1 to 7 for use in a method of preventing or treating HPV infection or cervical cancer in a subject, the method comprising administering a therapeutically effective amount of the chimaeric HPV VLP to the subject.

15. The chimaeric HPV VLP of claim 14, the method further comprising a step of eliciting an immune response in the subject.

16. The chimaeric HPV VLP of claim 15, wherein the immune response is a neutralising antibody response or a cytotoxic T lymphocyte response.

17. The chimaeric HPV VLP of claim 15, wherein the immune response is a cross-protective immune response to multiple HPV types present in the subject.

18. The chimaeric HPV VLP of any one of claims 14 to 17, wherein the subject is human.

19. The use of chimaeric HPV VLP of any one of claims 1 to 7 in the manufacture of a medicament for use in a method of preventing or treating HPV infection or cervical cancer in a subject, the method comprising administering a therapeutically effective amount of the medicament to the subject.

20. The use of claim 19, the method further comprising a step of eliciting an immune response in the subject.

21. The use of claim 20, wherein the immune response is a neutralising antibody response or a cytotoxic T lymphocyte response.

22. The use of claim 20, wherein the immune response is a cross-protective immune response to multiple HPV types present in the subject.

23. The use of any one of claims 19 to 22, wherein the subject is human.

24. A pharmaceutical composition comprising the chimaeric HPV VLP of any one of claims 1 to 7 and a pharmaceutically acceptable carrier or adjuvant.